Ticker

Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market…

Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development

ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it intends to change the ratio of American Depositary…

Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 125,042 shares, an increase of 29.9% from the January 15th total of 96,234 shares. Based on an average daily volume of 115,523 shares, the short-interest ratio is

Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT) shares are going to reverse split on the morning of Monday, March 2nd. The 1-10 reverse split was announced on Wednesday, February 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, March 1st. Purple Biotech Trading Up 0.5%